“Behandling med DT56a (Femarelle®) resulterte i en signifikant reduksjon i antallet og intensiteten av hetetokter hos kvinner i overgangsalderen… i løpet av første behandlingsmåned.”
A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms.
A statistically significant (p < 0.01) reduction in the number and intensity of hot flushes was
experienced after 2 and 4 weeks of DT56atreatment. After 4 weeks of treatment
with DT56a, 80.7% of the patients reported that their hot flushes were ‘better’ or ‘much
better’. The severity of hot flushes was also reduced by 38% in all study participants and by
36% in women who had experienced more than seven hot flushes per day initially, before